kabutan

KAKEN PHARMACEUTICAL CO.,LTD.(4521) Summary

4521
TSE Prime
KAKEN PHARMACEUTICAL CO.,LTD.
3,780
JPY
+15
(+0.40%)
Jun 5, 3:30 pm JST
23.63
USD
Jun 5, 2:30 am EDT
Result
PTS
outside of trading hours
Summary Chart Historical News Financial Result
PER
22.0
PBR
0.97
Yield
5.03%
Margin Trading Ratio
2.03
Stock Price
Jun 5, 2026
Opening Jun 5, 9:00 am
3,800 JPY 23.75 USD
Previous Close Jun 4
3,765 JPY 23.55 USD
High Jun 5, 9:54 am
3,850 JPY 24.07 USD
Low Jun 5, 2:44 pm
3,770 JPY 23.56 USD
Volume
80,800
Trading Value
0.31B JPY 1.92M USD
VWAP
3800.66 JPY 23.76 USD
Minimum Trading Value
378,000 JPY 2,363 USD
Market Cap
0.17T JPY 1.05B USD
Number of Trades
280
Liquidity & Number of Trades
As of Jun 5, 2026
Liquidity
Slightly High
1-Year Average
410
1-Year High Sep 29, 2025
1,445
Margin Trading
Date Short Interest Long Margin Positions Ratio
May 29, 2026 27,000 54,800 2.03
May 22, 2026 44,400 44,200 1.00
May 15, 2026 94,200 49,900 0.53
May 1, 2026 108,700 54,200 0.50
Apr 24, 2026 76,000 53,000 0.70
Company Profile
KAKEN PHARMACEUTICAL CO.,LTD. is a mid-sized pharmaceutical company. Its main products include joint function improvement agents and onychomycosis medications. The company also develops generic drugs and agricultural chemicals.
Sector
Pharmaceuticals
KAKEN PHARMACEUTICAL CO.,LTD. primarily engages in the pharmaceutical business, manufacturing and selling pharmaceuticals, medical devices, and agricultural chemicals. The company operates as a group that includes itself and two consolidated subsidiaries. In the pharmaceutical segment, Kaken Pharma and Asam handle manufacturing and sales. Additionally, the company is involved in the real estate business. The group as a whole focuses on the medical field while diversifying into areas such as agriculture. As a mid-sized player in the pharmaceutical industry, KAKEN PHARMACEUTICAL CO.,LTD. has established a unique product lineup and business structure, with its main products including the joint function improvement agent "ARTZ" and the onychomycosis treatment "Clenafin."